Streetbeat News

Price Targets

ALNY

Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $283 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:27 pm

GPN

TD Cowen analyst Bryan Bergin maintains a Buy rating on Global Payments (NYSE:GPN) but lowers the price target from $152 to $125.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:26 pm

RLI

Keefe, Bruyette & Woods analyst Meyer Shields maintains an Outperform rating on RLI (NYSE:RLI) with a $168 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:22 pm

CABA

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Cabaletta Bio (NASDAQ:CABA) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:19 pm

KKR

Keefe, Bruyette & Woods analyst Kyle Voigt maintains an Outperform rating on KKR (NYSE:KKR) with a $116 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:18 pm

ALL

Keefe, Bruyette & Woods analyst Meyer Shields maintains an Outperform rating on Allstate (NYSE:ALL) with a $194 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:16 pm

SRPT

Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $128.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:15 pm

HLLY

Canaccord Genuity analyst Brian McNamara maintains a Buy rating on Holley (NYSE:HLLY) with a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 3:11 pm